Transgene, Beckman Coulter ink agreement for development of companion diagnostic test for TG4010.

(From Pharma)

M2PHARMA-January 5, 2011-Transgene, Beckman Coulter ink agreement for development of companion diagnostic test for TG4010 (C)2011 M2 COMMUNICATIONS http://www.m2.com

5 January 2011 - French biopharmaceutical company Transgene (EPA: TNG) said today it has inked an agreement with US Beckman Coulter Inc (NYSE: BEC), under which Beckman Coulter will develop for Transgene a companion test that measures the level of activated Natural Killer (aNK) cells in order to select patients to be treated with TG4010.

The companion test will measure triple positive (CD16+, CD56+, CD69+ / CD45+ lymphocytes) activated NK cells (the aNK Test). It will come in …